Bookmark
Forward
QuickView for Lenalidomide (compound)
PubChem
| Name: | lenalidomide |
|---|---|
| PubChem Compound ID: | 216326 |
| Molecular formula: | C13H13N3O3 |
| Molecular weight: | 259.261 g/mol |
| Synonyms: |
CC-5013; Lenalidomide; 346670-73-3; IMID-5013; Revimid; 443912-14-9; CC 5013; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; CDC 501.
show more » |
DrugBank
Identification
| Name: | lenalidomide |
|---|---|
| Name (isomeric): | DB00480 |
| Drug Type: | small molecule |
| Synonyms: |
CDC 501; CC-5013; IMiD3
|
| Brand: | Revimid, Revlimid, Revlimid (Celgene) |
| Category: | Antineoplastic Agents |
| CAS number: | 191732-72-6 |
Pharmacology
| Indication: | For the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. |
|---|---|
| Pharmacology: |
Lenalidomide, a thalidomide analogue, is an immunomodulatory agent possessing immunomodulatory and antiangiogenic properties. Lenalidomide inhibits the secretion of pro-inflammatory cytokines and increases the secretion of anti-inflammatory cytokines from peripheral blood mononuclear cells. Lenalidomide inhibits cell proliferation with varying effe...
show more » |
| Mechanism of Action: |
The mechanism of action of lenalidomide remains to be fully characterized, however it has been demonstrated that lenalidomide inhibits the expression of cyclooxygenase-2 (COX-2), but not COX-1, in vitro. In vivo it induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-ost...
show more » |
| Absorption: | Rapidly absorbed following oral administration, with maximum plasma concentrations occurring between 0.625 and 1.5 hours post-dose. Co-administration with food does not alter the extent of absorption (AUC) but does reduce the maximal plasma concentration (Cmax) by 36%. The pharmacokinetic disposition of lenalidomide is linear. |
| Protein binding: | 30% |
| Biotransformation: | The metabolic profile of lenalidomide in humans has not been studied. In healthy volunteers, approximately two-thirds of lenalidomide is eliminated unchanged through urinary excretion. The process exceeds the glomerular filtration rate and therefore is partially or entirely active. |
| Route of elimination: | In healthy volunteers, approximately two-thirds of lenalidomide is eliminated unchanged through urinary excretion. |
| Half Life: | 3 hours |
| Toxicity: | The most frequently reported adverse events were related to blood and lymphatic system disorders, skin and subcutaneous tissue disorders, gastrointestinal disorders, and general disorders and administrative site conditions. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
